Abstract
Significant progress has been made in several areas of our lives within the last few decades: machine learning and artificial intelligence methods, data storage and transmission approaches, computational hardware, biotech, and drug discovery. All these advances combined unlock the potential for artificial intelligence to become a paradigm-shifting technology for drug discovery. Current obstacles in traditional drug discovery, the potential impact of AI on drug discovery, core differentiating factors of AI over traditional algorithms, and the latest advances in drug discovery with AI are discussed in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brown, T., Mann, B., Ryder, N., Subbiah, M., Kaplan, J. D., Dhariwal, P., et al. (2020). Language models are few-shot learners. Advances in Neural Information Processing Systems, 33, 1877–1901.
Design, B. (n.d.). First-ever computationally designed antibody, created by biolojic design, entering human clinical trial in cancer patients — prnewswire.com. https://www.prnewswire.com/news-releases/first-ever-computationally-designed-antibody-created-by-biolojic-design -entering-human-clinical-trial-in-cancer-patients-301517389.html. Accessed 04.01.23.
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22(2), 151–185.
Exscientia. (n.d.-a). Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI — investors.exscientia.ai. https://investors.exscientia.ai/press-releases/press-release-details/2022/Professor-Charlotte-Deane-Joins-Exscientia-as-Chief-Scientist-of-Biologics-AI/default.aspx. Accessed 04.01.23.
Exscientia. (n.d.-b). Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Trial — investors.exscientia.ai. https://investors.exscientia.ai/press-releases/press-release-details/2020/sumitomo-dainippon-pharma-and-exscientia-joint-development-new-drug-candidate-created-using-artificial-intelligence-ai-begins-clinical-trial/Default.aspx. Accessed 04.01.23.
Garcia-Sanchez, P., Mora, A. M., Castillo, P. A., & Perez, I. J. (2019). A bibliometric study of the research area of videogames using dimensions. ai database. Procedia Computer Science, 162, 737–744.
He, K., Zhang, X., Ren, S., & Sun, J. (2016). Deep residual learning for image recognition. Proceedings of the ieee conference on computer vision and pattern recognition (pp. 770–778).
Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British Journal of Pharmacology, 162(6), 1239–1249.
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., et al. (2021). Highly accurate protein structure prediction with alphafold. Nature, 596(7873), 583–589.
Medicine, I. (n.d.-a). From Start to Phase 1 in 30 Months. Insilico Medicine — insilico.com. https://insilico.com/phase1. Accessed 19.02.23
Medicine, I. (n.d.-b). Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018–055, an AI-designed drug for an AI-discovered target — globenewswire.com. https://www.globenewswire.com/news-release/2023/01/10/2586249/31533/en/Insilico-Medicine-announces-positive-topline-results-of-the-New-Zealand-Phase-1-trial-of-INS018 055-an-AI-designed-drug-for-an-AI-discovered-target.html. Artificial Intelligence Is a Game Changer In Drug Discovery R&D. Accessed 19.02.23.
Ramesh, A., Dhariwal, P., Nichol, A., Chu, C., & Chen, M. (2022). Hierarchical text-conditional image generation with clip latents. arXiv. Retrieved from https://arxiv.org/abs/2204.06125. https://doi.org/10.48550/ARXIV.2204.06125
Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J., & Baumann, M. (2021). How much does it cost to research and develop a new drug? A systematic review and assessment. PharmacoEconomics, 39, 1243–1269.
Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., et al. (2020). Improved protein structure prediction using potentials from deep learning. Nature, 577(7792), 706–710.
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022). Why 90% of clinical drug development fails and how to improve it? Acta Pharmaceutica Sinica B., 12(7), 3049–3062.
Takeda. (n.d.). Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease — takeda.com. https://www.takeda.com/newsroom/newsreleases/2020/takeda-acquires-pvp-biologics-following-results-of-a%2D%2Dphase-1-study-of-tak-062-kuma062-for-the-treatment-of-celiac-disease. Accessed 18.02.2023.
Vaswani, A., Shazeer, N., Parmar, N., Uszkoreit, J., Jones, L., Gomez, A. N., et al. (2017). Attention is all you need. Advances in Neural Information Processing Systems, 30, 15.
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., et al. (2019). Deep learning enables rapid identification of potent ddr1 kinase inhibitors. Nature Biotechnology, 37(9), 1038–1040.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ermak, T. (2024). Artificial Intelligence Is a Game Changer in Drug Discovery R&D. In: Schönbohm, A., von Horsten, H.H., Plugmann, P., von Stosch, M. (eds) Innovation in Life Sciences. Management for Professionals. Springer, Cham. https://doi.org/10.1007/978-3-031-47768-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-031-47768-3_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-47767-6
Online ISBN: 978-3-031-47768-3
eBook Packages: Business and ManagementBusiness and Management (R0)